Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefoxitin Sodium

FDA-approved product (injectable, injection), marketed as Cefoxitin, Cefoxitin And Dextrose In Duplex Container, Cefoxitin In Plastic Container and 4 more.

Registered studies
29
Lab records
132
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefoxitin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC01

Repurposing investigation

Cefoxitin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

29registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 5 of 10 lab records
  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 32 of 121 lab records
Open Cefoxitin Sodium in ChEMBL Registered studies below
Show the 132 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefoxitin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient

    NCT02958059 · start 2016-12-01

    Registered record
    Registry ID
    NCT02958059
    Conditions
    Biliary Obstructive Disease Such as Choledocholithiasis; Benign Biliary Stricture; Peri-ampullary Cancer; Bile Duct Cancer Resectable; Klatskin Tumor
    Interventions
    Pacetin® (cefoxitin); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-12-01
    Completion
    2020-08
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Obstructive Disease Such as Choledocholithiasis; Benign Biliary Stricture; Peri-ampullary Cancer; Bile Duct Cancer Resectable +1 more
    InterventionPacetin® (cefoxitin); Placebo
    PhaseNot applicable
    Registry statusUnknown

  • The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

    NCT02800785 · start 2016-05

    Registered record
    Registry ID
    NCT02800785
    Conditions
    Appendicitis
    Interventions
    Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin; Appendectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-05
    Completion
    2021-09-01
    Enrolment
    1,552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendicitis
    InterventionCefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin; Appendectomy
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

    NCT02474706 · start 2016-03

    Registered record
    Registry ID
    NCT02474706
    Conditions
    Urinary Tract Infections
    Interventions
    Cefoxitin; imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2017-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCefoxitin; imipenem
    PhasePhase 4
    Registry statusTerminated

  • Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

    NCT02703857 · start 2016-02

    Registered record
    Registry ID
    NCT02703857
    Conditions
    Antibiotic Prophylaxis Surgery
    Interventions
    cefoxitin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-09-20
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Prophylaxis Surgery
    Interventioncefoxitin
    PhasePhase 4
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

    NCT02985086 · start 2013-07

    Registered record
    Registry ID
    NCT02985086
    Conditions
    Maternal Infection During Pregnancy (Diagnosis); Neonatal Infection
    Interventions
    Cefoxitin; oxytocin/misoprostol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-07
    Completion
    2018-07
    Enrolment
    568

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMaternal Infection During Pregnancy (Diagnosis); Neonatal Infection
    InterventionCefoxitin; oxytocin/misoprostol
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

    NCT01820793 · start 2013-05

    Registered record
    Registry ID
    NCT01820793
    Conditions
    Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
    Interventions
    Cefoxitin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2015-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
    InterventionCefoxitin
    PhaseNot applicable
    Registry statusTerminated

  • Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis

    NCT01551394 · start 2012-09

    Registered record
    Registry ID
    NCT01551394
    Conditions
    Sepsis
    Interventions
    Meropenem; Ampicillin + gentamicin or cefotaxime + gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-12
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionMeropenem; Ampicillin + gentamicin or cefotaxime + gentamicin
    PhasePhase 3
    Registry statusCompleted

  • Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

    NCT01640886 · start 2012-06

    Registered record
    Registry ID
    NCT01640886
    Conditions
    Bacteremia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2012-06
    Completion
    2012-12
    Enrolment
    764

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

    NCT01426191 · start 2011-08

    Registered record
    Registry ID
    NCT01426191
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections
    Interventions
    xinzhijun
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-08
    Completion
    2016-12
    Enrolment
    2,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections
    Interventionxinzhijun
    PhaseNot recorded
    Registry statusCompleted

  • Effect of, OAT3, on the Renal Secretion of Cefotaxime

    NCT00187655 · start 2004-01

    Registered record
    Registry ID
    NCT00187655
    Conditions
    Focus Groups
    Interventions
    Cefotaxime
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-01
    Completion
    2013-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocus Groups
    InterventionCefotaxime
    PhasePhase 1
    Registry statusCompleted

  • Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs

    NCT00186082 · start 2003-09

    Registered record
    Registry ID
    NCT00186082
    Conditions
    Pregnancy Complications, Infectious
    Interventions
    Cefotetan or Cefoxitin vs placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2008-06
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy Complications, Infectious
    InterventionCefotetan or Cefoxitin vs placebo
    PhaseNot applicable
    Registry statusCompleted

  • Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women

    NCT00343317 · start 2003-02

    Registered record
    Registry ID
    NCT00343317
    Conditions
    Puerperal Sepsis
    Interventions
    Intrapartum Cefoxitin (2g) vs. placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-02
    Completion
    2005-05
    Enrolment
    1,372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPuerperal Sepsis
    InterventionIntrapartum Cefoxitin (2g) vs. placebo
    PhaseNot applicable
    Registry statusCompleted

  • Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia

    NCT01042353

    Registered record
    Registry ID
    NCT01042353
    Conditions
    Ventilator Acquired Pneumonia
    Interventions
    E test; standard culture method
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Acquired Pneumonia
    InterventionE test; standard culture method
    PhasePhase 4
    Registry statusCompleted